The Protein Folding Breakthrough and What It Actually Enables
December 14, 2025 · Frisian News
DeepMind's protein folding models have solved a decades-old puzzle, but the real-world applications remain limited and expensive. Drug companies still need to prove these tools cut development costs and timelines.
In late 2020, DeepMind announced it could predict how proteins fold in three dimensions with stunning accuracy. The breakthrough seemed to promise a new era in medicine and biology. Yet five years later, most drug developers still work the old way. Protein folding solves one problem. It does not automatically turn that knowledge into working drugs or cheaper research.
The machines know the shape now. Knowing a protein's final form tells scientists what it might do, but not how to use that information to treat disease. A pharmaceutical company still needs to screen millions of compounds, run countless tests, and navigate regulatory approval. The cost of bringing a drug from lab to pharmacy has barely budged. Most estimates place drug development at 1 to 3 billion dollars per approved medicine, unchanged from a decade ago.
Some companies have built tools around these folding models. They use AI to predict which drug candidates will work, which should fail, and which warrant lab testing. This workflow does save time in early stages. But the actual bottleneck happens later, in animal trials and human studies, where regulation and biology slow everything down. No algorithm predicts how a human body will react to a new compound. No computer avoids a failed trial.
The real winners so far have been academic researchers and smaller biotech firms that lack big budgets. They can now study protein structure without spending millions on lab equipment. Universities in poor countries can now model diseases once out of reach. That matters, even if it does not revolutionize the drug industry overnight. Knowledge spreads faster when tools become cheap.
Investors and tech firms hyped protein folding as a game changer. It was a game changer, but for different reasons than advertised. The tool works. The applications in medicine remain modest and years away. Anyone claiming these models have already cut drug costs or doubled innovation speed is selling hype, not science.
Yn 'e lette herfst fan 2020 kundige DeepMind oan dat it koenen foarsizze koude hoe proteïnen him yn trije dimensjes folje mei ferbluffende krektens. De trochbraak liek in nij tydperk yn medisine en biologyske wittenskip yn te leiden. Mar fiif jier letter wurkje de measte medisijnmakkers noch op de âlde wize. Proteïnfolding lost ien probleem op. It liedt net automatysk ta wurkende medisinen of goedkoper ûndersiik. De masines kenne de foarm no. It witen fan de slotfoarm fan in proteïn fertelt wittenskippers wat it mochte dwaan, mar net hoe't se dy ynformaasje brûke moatte om sykte te behandelen. In farmabedriiuw moat noch altyd miljoen ferbiningen skrinne, tûzenen toetsen útfiere en regelgeving navigearje. De kosten foar it bringen fan in medisyn fan it lab nei de apoteek binne nau net feroaret. De measte skatting pleatsje medisyn-ûndersiik op 1 oant 3 miljard dollar per goedkard medisyn, net feroaret fan in desennium lyn.
Summe bedriuwen hawwe ark om dizze vouwmodellen bouwd. Se brûke KI om foar te sizzen hokker medisyn-kandidaten suksessje, hokker moatte mislukke en hokker labûndersiken rjochtfardigje. Dizze workflow besparret yndie tiid yn iere stadia. Mar it werklike knelpunt komt letter, yn dierprueven en minsklike stúdzjes, wêr regelgeving en biologyske brems alles fertraget. Gjin algoritme foarsizze hoe in minsklik lichem op in nije stof regearret. Gjin kompjûter foarkimmet in mislearre eksperimint.
De echte winners oant no ta binne akademyske ûndersikkers en lytse biotechtbedriuwen sûnder grutte budgetten. Se kinne no proteïnstruktuer studearje sûnder miljoen út te jaan oan laboratorium-apparatuer. Universiteiten yn arme lannen kinne no sykten modelleare dy't ea onberiking wiene. Dat is wichtich, alhoewol it de medisyn-yndustrie net oannacht fan de iene dei op de oare fernueje. Kennis ferspriedt him hurder as ark goedkoop wurdt.
Beleggers en techbedriuwen hawwe proteïnfolding as game changer promovearre. It wie in game changer, mar om oare redenen dan advertearre. It ark wurket. De tapassingen yn medisine bliuwe beskaat en lizzje noch jierren fuort. Elkenien dy't bewearet dat dizze modellen medisyn-kosten al ferleget of ynnovaasje dûbele hân, ferkeapet hype, net wittenskip.
Published December 14, 2025 · Frisian News · Ljouwert, Fryslân